CASTLE BIOSCIENCES, INC. Research and Development Expense
CASTLE BIOSCIENCES, INC. (CSTL) reported Research and Development Expense of $14.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $14.54M, a 13.73% increase year-over-year.
- CASTLE BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $14.43M, a 14.62% increase year-over-year.
- CASTLE BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $13.52M, a 14.80% increase year-over-year.
- CASTLE BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $12.96M, a 5.17% increase year-over-year.
- CASTLE BIOSCIENCES, INC. research and development expense for fiscal 2025 was $51.85M, a 0.37% decline from fiscal 2024.
- CASTLE BIOSCIENCES, INC. research and development expense for fiscal 2024 was $52.04M, a 2.94% decline from fiscal 2023.
- CASTLE BIOSCIENCES, INC. research and development expense for fiscal 2023 was $53.62M, a 19.41% increase from fiscal 2022.
- CASTLE BIOSCIENCES, INC. research and development expense for fiscal 2022 was $44.90M, a 51.46% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.54M 10-Q · filed 2026-07-30 | $28.97M 10-Q · filed 2026-07-30 | $42.49M derived: sum of 3 quarters · filed 2026-07-30 | $55.45M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $14.43M 10-Q · filed 2026-05-06 | $27.94M derived: sum of 2 quarters · filed 2026-05-06 | $40.90M derived: sum of 3 quarters · filed 2026-05-06 | $53.69M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-12-31 | $13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.48M derived: sum of 2 quarters · filed 2026-02-26 | $39.26M derived: sum of 3 quarters · filed 2026-07-30 | $51.85M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $12.96M 10-Q · filed 2025-11-03 | $25.75M derived: sum of 2 quarters · filed 2026-07-30 | $38.34M 10-Q · filed 2025-11-03 | $50.11M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-06-30 | $12.79M 10-Q · filed 2026-07-30 | $25.38M 10-Q · filed 2026-07-30 | $37.15M derived: sum of 3 quarters · filed 2026-07-30 | $49.47M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-03-31 | $12.59M 10-Q · filed 2026-05-06 | $24.36M derived: sum of 2 quarters · filed 2026-05-06 | $36.68M derived: sum of 3 quarters · filed 2026-05-06 | $50.82M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.10M derived: sum of 2 quarters · filed 2026-02-26 | $38.23M derived: sum of 3 quarters · filed 2026-02-26 | $52.04M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $12.32M 10-Q · filed 2025-11-03 | $26.46M derived: sum of 2 quarters · filed 2025-11-03 | $40.27M 10-Q · filed 2025-11-03 | $53.26M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $14.14M 10-Q · filed 2025-08-04 | $27.95M 10-Q · filed 2025-08-04 | $40.94M derived: sum of 3 quarters · filed 2026-02-26 | $53.86M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $13.81M 10-Q · filed 2025-05-05 | $26.80M derived: sum of 2 quarters · filed 2026-02-26 | $39.73M derived: sum of 3 quarters · filed 2026-02-26 | $53.03M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $12.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.92M derived: sum of 2 quarters · filed 2026-02-26 | $39.23M derived: sum of 3 quarters · filed 2026-02-26 | $53.62M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $12.92M 10-Q · filed 2024-11-04 | $26.23M derived: sum of 2 quarters · filed 2024-11-04 | $40.62M 10-Q · filed 2024-11-04 | $51.93M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $13.31M 10-Q · filed 2024-08-05 | $27.70M 10-Q · filed 2024-08-05 | $39.01M derived: sum of 3 quarters · filed 2025-02-27 | $49.92M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $14.39M 10-Q · filed 2024-05-02 | $25.70M derived: sum of 2 quarters · filed 2025-02-27 | $36.61M derived: sum of 3 quarters · filed 2025-02-27 | $48.53M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $11.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $22.22M derived: sum of 2 quarters · filed 2025-02-27 | $34.14M derived: sum of 3 quarters · filed 2025-02-27 | $44.90M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $10.91M 10-Q · filed 2023-11-02 | $22.83M derived: sum of 2 quarters · filed 2023-11-02 | $33.59M 10-Q · filed 2023-11-02 | $43.04M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $11.93M 10-Q · filed 2023-08-02 | $22.69M 10-Q · filed 2023-08-02 | $32.13M derived: sum of 3 quarters · filed 2023-08-02 | $39.63M derived: sum of 4 quarters · filed 2023-08-02 | |||
| 2022-03-31 | $10.76M 10-Q · filed 2023-05-03 | $20.21M derived: sum of 2 quarters · filed 2023-05-03 | $27.71M derived: sum of 3 quarters · filed 2023-05-03 | $34.50M derived: sum of 4 quarters · filed 2023-05-03 | |||
| 2021-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $16.95M derived: sum of 2 quarters · filed 2023-02-28 | $23.74M derived: sum of 3 quarters · filed 2023-02-28 | $29.65M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $7.50M 10-Q · filed 2022-11-02 | $14.29M derived: sum of 2 quarters · filed 2022-11-02 | $20.20M 10-Q · filed 2022-11-02 | $24.78M derived: sum of 4 quarters · filed 2022-11-02 | |||
| 2021-06-30 | $6.79M 10-Q · filed 2022-08-08 | $12.70M 10-Q · filed 2022-08-08 | $17.28M derived: sum of 3 quarters · filed 2022-08-08 | $20.34M derived: sum of 4 quarters · filed 2022-08-08 | |||
| 2021-03-31 | $5.91M 10-Q · filed 2022-05-09 | $10.49M derived: sum of 2 quarters · filed 2022-05-09 | $13.55M derived: sum of 3 quarters · filed 2022-05-09 | $16.25M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $7.64M derived: sum of 2 quarters · filed 2022-02-28 | $10.34M derived: sum of 3 quarters · filed 2022-02-28 | $13.26M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $3.06M 10-Q · filed 2021-11-08 | $5.76M derived: sum of 2 quarters · filed 2021-11-08 | $8.68M 10-Q · filed 2021-11-08 | $11.83M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $2.70M 10-Q · filed 2021-08-09 | $5.62M 10-Q · filed 2021-08-09 | $8.78M derived: sum of 3 quarters · filed 2021-08-09 | $10.29M derived: sum of 4 quarters · filed 2021-08-09 | |||
| 2020-03-31 | $2.91M 10-Q · filed 2021-05-10 | $6.07M derived: sum of 2 quarters · filed 2021-05-10 | $7.59M derived: sum of 3 quarters · filed 2021-05-10 | $8.90M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $4.67M derived: sum of 2 quarters · filed 2021-03-11 | $5.99M derived: sum of 3 quarters · filed 2021-03-11 | $7.38M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $1.51M 10-Q · filed 2020-11-09 | $1.51M 10-Q · filed 2019-11-12 | $2.83M derived: sum of 2 quarters · filed 2020-11-09 | $4.23M 10-Q · filed 2020-11-09 | $4.23M 10-Q · filed 2019-11-12 | $5.36M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $1.32M 10-Q · filed 2020-08-10 | $1.32M 10-Q · filed 2019-09-03 | $2.71M 10-Q · filed 2020-08-10 | $2.71M 10-Q · filed 2019-09-03 | $3.85M derived: sum of 3 quarters · filed 2020-08-10 | $5.14M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $1.39M 10-Q · filed 2020-05-11 | $2.53M derived: sum of 2 quarters · filed 2020-05-11 | $3.83M derived: sum of 3 quarters · filed 2020-05-11 | $4.99M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $2.43M derived: sum of 2 quarters · filed 2020-03-10 | $3.59M derived: sum of 3 quarters · filed 2020-03-10 | $4.85M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $1.29M 10-Q · filed 2019-11-12 | $2.45M derived: sum of 2 quarters · filed 2019-11-12 | $3.72M 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | $1.16M 10-Q · filed 2019-09-03 | $2.42M 10-Q · filed 2019-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |